Making KMT Hepatech, Inc. a wholly owned subsidiary
First written in FY2018-Q3. 1 of 2 entries say "Achieved", first in FY2018-Q3. Latest entry: FY2018.
No other company in this theme has enough history to compare yet.
- FY2018Cited as achievedAnnual report
「By making KMT Hepatech,Inc. a wholly owned subsidiary, the company will use KMT Hepatech,Inc.'s brand recognition across the sales network it has built in North America to further expand sales of PXB mice.」
The company reports the completed acquisition and conversion of KMT Hepatech,Inc. into a wholly owned subsidiary, effective 30 November 2017, and reconfirms its policy of expanding sales through its North American sales network. - FY2018-Q3AchievedAnnual report
「At a meeting of the Board of Directors held on 14 November 2017, the company resolved to acquire shares of KMT Hepatech,Inc. through a special-purpose acquisition company to be established in Canada and make KMT Hepatech,Inc. a wholly owned subsidiary. The company completed the execution of the share transfer agreement and the share acquisition on 30 November of the same year. By making KMT Hepatech,Inc. a wholly owned subsidiary, the company will use KMT Hepatech,Inc.'s brand recognition across the sales network it has built in North America to further expand sales of PXB mice.」
The company completed the acquisition of KMT Hepatech,Inc.'s shares and made it a wholly owned subsidiary on 30 November 2017. The acquired voting interest was 100%, and the acquisition consideration was ¥485,815 thousand. The company indicated a policy of using KMT's brand recognition through its existing North American sales network to expand sales of PXB mice.